Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
Quick Facts
What This Study Found
AM levels increase during inflammation but are less significant in CVDs; AM's half-life is under 30 minutes.
Key Numbers
How They Did This
The study is a review of existing research on adrenomedullin and its derivatives in relation to cardiovascular diseases.
Why This Research Matters
Understanding the role of AM in cardiovascular health could lead to better treatment options. The development of longer-lasting AM derivatives may enhance therapeutic applications.
What This Study Doesn't Tell Us
The short half-life of AM limits its therapeutic use, and early human studies have not been successful for CVD applications.
Trust & Context
- Original Title:
- Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
- Published In:
- Hypertension research : official journal of the Japanese Society of Hypertension, 45(3), 389-400 (2022)
- Authors:
- Kita, Toshihiro, Kitamura, Kazuo
- Database ID:
- RPEP-06256
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06256APA
Kita, Toshihiro; Kitamura, Kazuo. (2022). Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.. Hypertension research : official journal of the Japanese Society of Hypertension, 45(3), 389-400. https://doi.org/10.1038/s41440-021-00806-y
MLA
Kita, Toshihiro, et al. "Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.." Hypertension research : official journal of the Japanese Society of Hypertension, 2022. https://doi.org/10.1038/s41440-021-00806-y
RethinkPeptides
RethinkPeptides Research Database. "Translational studies of adrenomedullin and related peptides..." RPEP-06256. Retrieved from https://rethinkpeptides.com/research/kita-2022-translational-studies-of-adrenomedullin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.